CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside

OncoImmunology

Volumn 5, Issue 12, 2016, Pages

  Zhang, Qi ^a   Zhang, Zimu ^a   Peng, Meiyu ^b   Fu, Shuyu ^a   Xue, Zhenyi ^a   Zhang, Rongxin ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

CAR T cell; Chimeric antigen receptor (CAR); gastrointestinal cancer; hepatic carcinoma; immunotherapy

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; NEUROPILIN 1;

CELL THERAPY; CLINICAL PRACTICE; CYTOKINE RELEASE SYNDROME; GASTROINTESTINAL TUMOR; HUMAN; IMMUNE RESPONSE; LIVER CELL CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TUMOR DIFFERENTIATION;

EID: 85007414755     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1251539     Document Type: Review

References (104)

1. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013; 3:388-98; PMID:23550147; http://dx.doi.org/10.1158/2159-8290.CD-12-0548
2. Stauss HJ, Morris EC, Abken H. Cancer gene therapy with T cell receptors and chimeric antigen receptors. Curr Opin Pharmacol 2015; 24:113-8; PMID:26342910; http://dx.doi.org/10.1016/j.coph.2015.08.006
3. Turtle CJ, Hudecek M, Jensen MC, Riddell SR. Engineered T cells for anti-cancer therapy. Curr Opin Immunol 2012; 24:633-9; PMID:22818942; http://dx.doi.org/10.1016/j.coi.2012.06.004
4. Seliger B. Different regulation of MHC class I antigen processing components in human tumors. J Immunotoxicol 2008; 5:361-7; PMID:19404870; http://dx.doi.org/10.1080/15476910802482870
5. Patel JM, Dale GA, Vartabedian VF, Dey P, Selvaraj P. Cancer CARtography:charting out a new approach to cancer immunotherapy. Immunotherapy 2014; 6:675-8; PMID:25186600; http://dx.doi.org/10.2217/imt.14.44
6. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011; 121:1822-6; PMID:21540550; http://dx.doi.org/10.1172/JCI46110
7. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18:843-51; PMID:20179677; http://dx.doi.org/10.1038/mt.2010.24
8. Han EQ, Li XL, Wang CR, Li TF, Han SY. Chimeric antigen receptor-engineered T cells for cancer immunotherapy:progress and challenges. J Hematol Oncol 2013; 6:47; PMID:23829929; http://dx.doi.org/10.1186/1756-8722-6-47
9. Colovos C, Villena-Vargas J, Adusumilli PS. Safety and stability of retrovirally transduced chimeric antigen receptor T cells. Immunotherapy 2012; 4:899-902; PMID:23046233; http://dx.doi.org/10.2217/imt.12.91
10. Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE, Posey AD, Jr et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res 2015; 3:356-67; PMID:25600436; http://dx.doi.org/10.1158/2326-6066.CIR-14-0186
11. De Oliveira SN, Ryan C, Giannoni F, Hardee CL, Tremcinska I, Katebian B, Wherley J, Sahaghian A, Tu A, Grogan T, et al. Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy. Hum Gene Ther 2013; 24:824-39; PMID:23978226; http://dx.doi.org/10.1089/hum.2012.202
12. Maiti SN, Huls H, Singh H, Dawson M, Figliola M, Olivares S, Rao P, Zhao YJ, Multani A, Yang G, et al. Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother 2013; 36:112-23; PMID:23377665; http://dx.doi.org/10.1097/CJI.0b013e3182811ce9
13. Nakazawa Y, Huye LE, Salsman VS, Leen AM, Ahmed N, Rollins L, Dotti G, Gottschalk SM, Wilson MH, Rooney CM. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther 2011; 19:2133-43; PMID:21772253; http://dx.doi.org/10.1038/mt.2011.131
14. Tsukahara T, Iwase N, Kawakami K, Iwasaki M, Yamamoto C, Ohmine K, Uchibori R, Teruya T, Ido H, Saga Y, et al. The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies. Gene Ther 2015; 22:209-15; PMID:25427612; http://dx.doi.org/10.1038/gt.2014.104
15. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5:177ra38; PMID:23515080; http://dx.doi.org/10.1126/scitranslmed.3005930
16. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6:224ra25; PMID:24553386; http://dx.doi.org/10.1126/scitranslmed.3008226
17. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368:1509-18; PMID:23527958; http://dx.doi.org/10.1056/NEJMoa1215134
18. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015; 33:540-9; PMID:25154820; http://dx.doi.org/10.1200/JCO.2014.56.2025
19. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX:first clinical experience. J Clin Oncol 2006; 24:e20-2; PMID:16648493; http://dx.doi.org/10.1200/JCO.2006.05.9964
20. Lamers CH, Klaver Y, Gratama JW, Sleijfer S, Debets R. Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview. Biochem Soc Trans 2016; 44:951-9; PMID:27284065; http://dx.doi.org/10.1042/BST20160037
21. Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, Vulto A, den Bakker M, Oosterwijk E, Debets R, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells:clinical evaluation and management of on-target toxicity. Mol Ther 2013; 21:904-12; PMID:23423337; http://dx.doi.org/10.1038/mt.2013.17
22. Davila ML, Sadelain M. Biology and clinical application of CAR T cells for B cell malignancies. Int J Hematol 2016; 104:6-17; PMID:27262700; http://dx.doi.org/10.1007/s12185-016-2039-6
23. Dutcher J, Atkins MB, Margolin K, Weiss G, Clark J, Sosman J, Logan T, Aronson F, Mier J, Cytokine Working Group. Kidney cancer:the Cytokine Working Group experience (1986–2001):part II. Management of IL-2 toxicity and studies with other cytokines. Med Oncol 2001; 18:209-19; PMID:11917945; http://dx.doi.org/10.1385/MO:18:3:209
24. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124:188-95; PMID:24876563; http://dx.doi.org/10.1182/blood-2014-05-552729
25. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95ra73; PMID:21832238; http://dx.doi.org/10.1126/scitranslmed.3002842
26. Davila ML, Bouhassira DC, Park JH, Curran KJ, Smith EL, Pegram HJ, Brentjens R. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol 2014; 99:361-71; PMID:24311149; http://dx.doi.org/10.1007/s12185-013-1479-5
27. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119:2709-20; PMID:22160384; http://dx.doi.org/10.1182/blood-2011-10-384388
28. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371:1507-17; PMID:25317870; http://dx.doi.org/10.1056/NEJMoa1407222
29. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults:a phase 1 dose-escalation trial. Lancet 2015; 385:517-28; PMID:25319501; http://dx.doi.org/10.1016/S0140-6736(14)61403-3
30. Newick K, Moon E, Albelda SM. Chimeric antigen receptor T-cell therapy for solid tumors. Mol Ther Oncolytics 2016; 3:16006; PMID:27162934; http://dx.doi.org/10.1038/mto.2016.6
31. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells:recognition and management. Blood 2016; 127:3321-30; PMID:27207799; http://dx.doi.org/10.1182/blood-2016-04-703751
32. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med 2011; 364:1844-54; PMID:21561350; http://dx.doi.org/10.1056/NEJMra0904569
33. Cavazzana-Calvo M, Fischer A, Hacein-Bey-Abina S, Aiuti A. Gene therapy for primary immunodeficiencies:part 1. Curr Opin Immunol 2012; 24:580-4; PMID:22981681; http://dx.doi.org/10.1016/j.coi.2012.08.008
34. Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH, Powell DJ, Jr. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res 2013; 1:43-53; PMID:24409448; http://dx.doi.org/10.1158/2326-6066.CIR-13-0008
35. Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, Corder A, Schönfeld K, Koch J, Dotti G, et al. TanCAR:a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids 2013; 2:e105; PMID:23839099; http://dx.doi.org/10.1038/mtna.2013.32
36. Wilkie S, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol 2012; 32:1059-70; PMID:22526592; http://dx.doi.org/10.1007/s10875-012-9689-9
37. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013; 31:71-5; PMID:23242161; http://dx.doi.org/10.1038/nbt.2459
38. Duong CP, Westwood JA, Berry LJ, Darcy PK, Kershaw MH. Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. Immunotherapy 2011; 3:33-48; PMID:21174556; http://dx.doi.org/10.2217/imt.10.81
39. Liu X, Jiang S, Fang C, Yang S, Olalere D, Pequignot EC, Cogdill AP, Li N, Ramones M, Granda B, et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res 2015; 75:3596-607; PMID:26330166; http://dx.doi.org/10.1158/0008-5472.CAN-15-0159
40. Caruso HG, Hurton LV, Najjar A, Rushworth D, Ang S, Olivares S, Mi T, Switzer K, Singh H, Huls H, et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res 2015; 75:3505-18; PMID:26330164; http://dx.doi.org/10.1158/0008-5472.CAN-15-0139
41. Minagawa K, Zhou X, Mineishi S, Di Stasi A. Seatbelts in CAR therapy:how safe are CARS? Pharmaceuticals (Basel) 2015; 8:230-49; PMID:26110321; http://dx.doi.org/10.3390/ph8020230
42. Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med 2013; 5:215ra172; PMID:24337479; http://dx.doi.org/10.1126/scitranslmed.3006597
43. Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Puré E, Milone MC, June CH, et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res 2014; 20:4262-73; PMID:24919573; http://dx.doi.org/10.1158/1078-0432.CCR-13-2627
44. Jones BS, Lamb LS, Goldman F, Di Stasi A. Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol 2014; 5:254; PMID:25505885; http://dx.doi.org/10.3389/fphar.2014.00254
45. Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol 2014; 5:235; PMID:25389405; http://dx.doi.org/10.3389/fphar.2014.00235
46. Di Stasi A, Tey S-K, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011; 365:1673-83; PMID:22047558; http://dx.doi.org/10.1056/NEJMoa1106152
47. Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 2006; 107:2294-302; PMID:16282341; http://dx.doi.org/10.1182/blood-2005-08-3503
48. Traversari C, Marktel S, Magnani Z, Mangia P, Russo V, Ciceri F, Bonini C, Bordignon C. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 2007; 109:4708-15; PMID:17327417; http://dx.doi.org/10.1182/blood-2006-04-015230
49. Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007; 13:913-24; PMID:17640595; http://dx.doi.org/10.1016/j.bbmt.2007.04.005
50. Straathof KC, Pulè MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, Heslop HE, Spencer DM, Rooney CM. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005; 105:4247-54; PMID:15728125; http://dx.doi.org/10.1182/blood-2004-11-4564
51. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 2010; 70:9053-61; PMID:20926399; http://dx.doi.org/10.1158/0008-5472.CAN-10-2880
52. Birkholz K, Hombach A, Krug C, Reuter S, Kershaw M, Kämpgen E, Schuler G, Abken H, Schaft N, Dörrie J. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer. Gene Ther 2009; 16:596-604; PMID:19158846; http://dx.doi.org/10.1038/gt.2008.189
53. Di S, Li Z. Treatment of solid tumors with chimeric antigen receptor-engineered T cells:current status and future prospects. Sci China Life Sci 2016; 59:360-9; PMID:26968709; http://dx.doi.org/10.1007/s11427-016-5025-6
54. Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer:an update. World J Gastroenterol 2016; 22:4619-25; PMID:27217694; http://dx.doi.org/10.3748/wjg.v22.i19.4619
55. Kurokawa Y, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H, Kobayashi K, Yokoyama Y, Shaker MN, Takiguchi S, et al. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer 2015; 18:691-7; PMID:25224659; http://dx.doi.org/10.1007/s10120-014-0430-7
56. Sheffield BS, Garratt J, Kalloger SE, Li-Chang HH, Torlakovic EE, Gilks CB, Schaeffer DF. HER2/neu testing in gastric cancer by immunohistochemistry:assessment of interlaboratory variation. Arch Pathol Lab Med 2014; 138:1495-502; PMID:25357111; http://dx.doi.org/10.5858/arpa.2013-0604-OA
57. Zulfiqar M, Bhalla A, Weindel M, Shidham VB. Molecular diagnostics in esophageal and gastric neoplasms. Clin Lab Med 2013; 33:867-73; PMID:24267191; http://dx.doi.org/10.1016/j.cll.2013.08.006
58. Whilding LM, Maher J. ErbB-targeted CAR T-cell immunotherapy of cancer. Immunotherapy 2015; 7:229-41; PMID:25804476; http://dx.doi.org/10.2217/imt.14.120
59. Kobold S, Steffen J, Chaloupka M, Grassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger JC, Schnurr M, et al. Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer. J Natl Cancer Inst 2015; 107:364; PMID:25424197; http://dx.doi.org/10.1093/jnci/dju364
60. Maher J, Wilkie S. CAR mechanics:driving T cells into the MUC of cancer. Cancer Res 2009; 69:4559-62; PMID:19487277; http://dx.doi.org/10.1158/0008-5472.CAN-09-0564
61. Warneke VS, Behrens HM, Haag J, Krüger S, Simon E, Mathiak M, Ebert MP, Röcken C. Members of the EpCAM signalling pathway are expressed in gastric cancer tissue and are correlated with patient prognosis. Br J Cancer 2013; 109:2217-27; PMID:24008668; http://dx.doi.org/10.1038/bjc.2013.536
62. Deng Z, Wu Y, Ma W, Zhang S, Zhang YQ. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunol 2015; 16:1; PMID:25636521; http://dx.doi.org/10.1186/s12865-014-0064-x
63. Wu MR, Zhang T, DeMars LR, Sentman CL. B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity. Gene Ther 2015; 22:675-84; PMID:25830550; http://dx.doi.org/10.1038/gt.2015.29
64. Zheng HC, Zheng YS, Li XH, Takahashi H, Hara T, Masuda S, Yang XH, Guan YF, Takano Y. Arp2/3 overexpression contributed to pathogenesis, growth and invasion of gastric carcinoma. Anticancer Res 2008; 28:2225-32; PMID:18751399
65. Li L, Jiang X, Zhang Q, Dong X, Gao Y, He Y, Qiao H, Xie F, Xie X, Sun X, et al. Neuropilin-1 is associated with clinicopathology of gastric cancer and contributes to cell proliferation and migration as multifunctional co-receptors. J Exp Clin Cancer Res 2016; 35:16; PMID:26795388; http://dx.doi.org/10.1186/s13046-016-0291-5
66. Anami K, Oue N, Noguchi T, Sakamoto N, Sentani K, Hayashi T, Hinoi T, Okajima M, Graff JM, Yasui W. Search for transmembrane protein in gastric cancer by the Escherichia coli ampicillin secretion trap:expression of DSC2 in gastric cancer with intestinal phenotype. J Pathol 2010; 221:275-84; PMID:20527021; http://dx.doi.org/10.1002/path.2717
67. Xu WQ, Song LJ, Liu Q, Zhao L, Zheng L, Yan ZW, Fu GH. Expression of anion exchanger 1 is associated with tumor progress in human gastric cancer. J Cancer Res Clin Oncol 2009; 135:1323-30; PMID:19330352; http://dx.doi.org/10.1007/s00432-009-0573-9
68. Emtage PC, Lo ASY, Liu DL, Gomes EM, Gonzalo-Daganzo R, Junghans RP. Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo:a preclinical evaluation. Clin Cancer Res 2008; 14:8112-22; PMID:19088026; http://dx.doi.org/10.1158/1078-0432.CCR-07-4910
69. Zhu X, Prasad S, Gaedicke S, Hettich M, Firat E, Niedermann G. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57. Oncotarget 2015; 6:171-84; PMID:25426558; http://dx.doi.org/10.18632/oncotarget.2767
70. Feng K, Guo Y, Dai H, Wang Y, Li X, Jia H, Han W. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Sci China Life Sci 2016; 59:468-79; PMID:26968708; http://dx.doi.org/10.1007/s11427-016-5023-8
71. Frick GS, Pitari GM, Weinberg DS, Hyslop T, Schulz S, Waldman SA. Guanylyl cyclase C:a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev Mol Diagn 2005; 5:701-13; PMID:16149873; http://dx.doi.org/10.1586/14737159.5.5.701
72. Gong JP, Schulz S, Hyslop T, Waldman SA. GUCY2C molecular staging personalizes colorectal cancer patient management. Biomark Med 2012; 6:339-48; PMID:22731908; http://dx.doi.org/10.2217/bmm.12.24
73. Snook AE, Magee MS, Waldman SA. GUCY2C-targeted cancer immunotherapy:past, present and future. Immunol Res 2011; 51:161-9; PMID:22038530; http://dx.doi.org/10.1007/s12026-011-8253-7
74. Yan D, Wiesmann M, Rohan M, Chan V, Jefferson AB, Guo L, Sakamoto D, Caothien RH, Fuller JH, Reinhard C, et al. Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta-catenin signaling is activated in human colon tumors. Proc Natl Acad Sci USA 2001; 98:14973-8; PMID:11752446; http://dx.doi.org/10.1073/pnas.261574498
75. Lin F, Shi J, Zhu S, Chen Z, Li A, Chen T, Wang HL, Liu H. Cadherin-17 and SATB2 are sensitive and specific immunomarkers for medullary carcinoma of the large intestine. Arch Pathol Lab Med 2014; 138:1015-26; PMID:24437456; http://dx.doi.org/10.5858/arpa.2013-0452-OA
76. Taliano RJ, LeGolvan M, Resnick MB. Immunohistochemistry of colorectal carcinoma:current practice and evolving applications. Hum Pathol 2013; 44:151-63; PMID:22939578; http://dx.doi.org/10.1016/j.humpath.2012.04.017
77. Su MC, Yuan RH, Lin CY, Jeng YM. Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system. Mod Pathol 2008; 21:1379-86; PMID:18552820; http://dx.doi.org/10.1038/modpathol.2008.107
78. Thomas AM, Santarsiero LM, Lutz ER, Armstrong TD, Chen YC, Huang LQ, Laheru DA, Goggins M, Hruban RH, Jaffee EM. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004; 200:297-306; PMID:15289501; http://dx.doi.org/10.1084/jem.20031435
79. Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, Powell DJ, Jr. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther 2012; 20:633-43; PMID:22127019; http://dx.doi.org/10.1038/mt.2011.256
80. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2014; 2:112-20; PMID:24579088; http://dx.doi.org/10.1158/2326-6066.CIR-13-0170
81. Panjwani MK, Smith JB, Schutsky K, Gnanandarajah J, O'Connor CM, Powell DJ, Jr, Mason NJ. Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B cell lymphoma. Mol Ther 2016; 24(9):1602-14; PMID:27401141; http://dx.doi.org/10.1038/mt.2016.146
82. Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 2013; 1:26-31; PMID:24777247; http://dx.doi.org/10.1158/2326-6066.CIR-13-0006
83. Katari UL, Keirnan JM, Worth AC, Hodges SE, Leen AM, Fisher WE, Vera JF. Engineered T cells for pancreatic cancer treatment. HPB (Oxford) 2011; 13:643-50; PMID:21843265; http://dx.doi.org/10.1111/j.1477-2574.2011.00344.x
84. Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, Burns WR, Miermont AM, Teper Y, Rudloff U, et al. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther 2014; 25:1003-12; PMID:24694017; http://dx.doi.org/10.1089/hum.2013.209
85. Chmielewski M, Hahn O, Rappl G, Nowak M, Schmidt-Wolf IH, Hombach AA, Abken H, et al. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology 2012; 143:1095-107.e2; PMID:22750462; PMID:22750462; http://dx.doi.org/10.1053/j.gastro.2012.06.037
86. Maliar A, Servais C, Waks T, Chmielewski M, Lavy R, Altevogt P, Abken H, Eshhar Z. Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology 2012; 143:1375-84.e1-5; http://dx.doi.org/10.1053/j.gastro.2012.07.017
87. Posey AD, Jr, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, Stone JD, Madsen TD, Schreiber K, Haines KM, et al. Engineered CAR T cells targeting the cancer-associated Tn-Glycoform of the membrane mucin muc1 control adenocarcinoma. Immunity 2016; 44:1444-54; PMID:27332733; http://dx.doi.org/; http://dx.doi.org/10.1016/j.immuni.2016.05.014
88. Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, Ittmann MM, Marchetti D, Dotti G. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med 2015; 21:524-9; PMID:25849134; http://dx.doi.org/10.1038/nm.3833
89. Torres MP, Chakraborty S, Souchek J, Batra SK. Mucin-based targeted pancreatic cancer therapy. Curr Pharm Des 2012; 18:2472-81; PMID:22372499; http://dx.doi.org/10.2174/13816128112092472
90. Andrianifahanana M, Moniaux N, Schmied BM, Ringel J, Friess H, Hollingsworth MA, Büchler MW, Aubert JP, Batra SK. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis:a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res 2001; 7:4033-40; PMID:11751498
91. Koneru M, O'Cearbhaill R, Pendharkar S, Spriggs DR, Brentjens RJ. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med 2015; 13:102; PMID:25890361; http://dx.doi.org/10.1186/s12967-015-0460-x
92. Pardee AD, Butterfield LH. Immunotherapy of hepatocellular carcinoma:Unique challenges and clinical opportunities. Oncoimmunology 2012; 1:48-55; PMID:22720211; http://dx.doi.org/10.4161/onci.1.1.18344
93. Burga RA, Thorn M, Point GR, Guha P, Nguyen CT, Licata LA, DeMatteo RP, Ayala A, Joseph Espat N, Junghans RP, et al. Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol Immunother 2015; 64:817-29; PMID:25850344; http://dx.doi.org/10.1007/s00262-015-1692-6
94. Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR, Khare PD, Thorn M, Ma Q, Stainken BF, et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin Cancer Res 2015; 21:3149-59; PMID:25850950; http://dx.doi.org/10.1158/1078-0432.CCR-14-1421
95. Gao H, Li K, Tu H, Pan X, Jiang H, Shi B, Kong J, Wang H, Yang S, Gu J, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res 2014; 20:6418-28; PMID:25320357; http://dx.doi.org/; http://dx.doi.org/10.1158/1078-0432.CCR-14-1170
96. Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, Miyoshi E, Monden M, Matsuura N. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001; 84:1377-83; PMID:11355950; http://dx.doi.org/10.1054/bjoc.2000.1580
97. Krebs K, Böttinger N, Huang LR, Chmielewski M, Arzberger S, Gasteiger G, Jäger C, Schmitt E, Bohne F, Aichler M, et al. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology 2013; 145:456-65; PMID:23639914; http://dx.doi.org/10.1053/j.gastro.2013.04.047
98. Behne T, Copur MS. Biomarkers for hepatocellular carcinoma. Int J Hepatol 2012; 2012:859076; PMID:22655201; http://dx.doi.org/10.1155/2012/859076
99. Khien VV, Mao HV, Chinh TT, Ha PT, Bang MH, Lac BV, Hop TV, Tuan NA, Don LV, Taketa K, et al. Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma. Int J Biol Markers 2001; 16:105-11; PMID:11471892
100. Xia QY, Liu S, Li FQ, Huang WB, Shi LN, Zhou XJ. Sperm protein 17, MAGE-C1 and NY-ESO-1 in hepatocellular carcinoma:expression frequency and their correlation with clinical parameters. Int J Clin Exp Pathol 2013; 6:1610-6; PMID:23923079
101. Blat D, Zigmond E, Alteber Z, Waks T, Eshhar Z. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Mol Ther 2014; 22:1018-28; PMID:24686242; http://dx.doi.org/10.1038/mt.2014.41
102. Anurathapan U, Chan RC, Hindi HF, Mucharla R, Bajgain P, Hayes BC, Fisher WE, Heslop HE, Rooney CM, Brenner MK, et al. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther 2014; 22:623-33; PMID:24213558; http://dx.doi.org/10.1038/mt.2013.262
103. Katz SC, Point GR, Cunetta M, Thorn M, Guha P, Espat NJ, Boutros C, Hanna N, Junghans RP. Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery. Cancer Gene Ther 2016; 23:142-8; PMID:27080226; http://dx.doi.org/10.1038/cgt.2016.14
104. Yang X, Takano Y, Zheng HC. The pathobiological features of gastrointestinal cancers (Review). Oncol Lett 2012; 3:961-9; PMID:22783373; http://dx.doi.org/10.3892/ol.2012.628